CASI - CASI Pharmaceuticals Inc - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

15.17M

Cash

44.29M

Avg Qtr Burn

N/A

Short % of Float

3.96%

Insider Ownership

37.46%

Institutional Own.

12.90%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
EVOMELA (melphalan) Details MM (Multiple Myeloma)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CNCT-19 (Anti-CD19) Details Non-Hodgkin lymphoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BI-1206 (Anti-FcyRIIB antibody) + rituximab Details Solid tumor/s, Non-Hodgkin lymphoma, Blood cancer, Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CB-5339 Details Multiple myeloma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.